Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.

Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL.

Ann Intern Med. 2012 Jun 19;156(12):861-74, W301-10. doi: 10.7326/0003-4819-156-12-201206190-00436. Review.

PMID:
22711079
[PubMed - indexed for MEDLINE]
2.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963
[PubMed - indexed for MEDLINE]
3.

Solifenacin for overactive bladder: a systematic review and meta-analysis.

Luo D, Liu L, Han P, Wei Q, Shen H.

Int Urogynecol J. 2012 Aug;23(8):983-91. doi: 10.1007/s00192-011-1641-7. Epub 2012 Feb 7. Review.

PMID:
22310924
[PubMed - indexed for MEDLINE]
4.

Pharmacologic management of overactive bladder.

Lam S, Hilas O.

Clin Interv Aging. 2007;2(3):337-45. Review.

PMID:
18044184
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness [Internet].

Shamliyan T, Wyman J, Kane RL.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr.

PMID:
22624162
[PubMed]
Books & Documents
6.
7.

Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.

Harvey MA, Baker K, Wells GA.

Am J Obstet Gynecol. 2001 Jul;185(1):56-61.

PMID:
11483904
[PubMed - indexed for MEDLINE]
8.

Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women.

Shamliyan TA, Kane RL, Wyman J, Wilt TJ.

Ann Intern Med. 2008 Mar 18;148(6):459-73. Epub 2008 Feb 11. Review. Erratum in: Ann Intern Med. 2011 Dec 6;155(11):796.

PMID:
18268288
[PubMed - indexed for MEDLINE]
9.

Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.

Swift SE, Siami P, Forero-Schwanhaeuser S.

Clin Drug Investig. 2009;29(5):305-16. doi: 10.2165/00044011-200929050-00003.

PMID:
19366272
[PubMed - indexed for MEDLINE]
10.

Elevating our therapeutic expectations in overactive bladder.

Sand PK.

J Am Acad Nurse Pract. 2004 Oct;16(10 Suppl):8-11. Review.

PMID:
15543927
[PubMed - indexed for MEDLINE]
11.

Update on drugs for overactive bladder syndrome.

[No authors listed]

Drug Ther Bull. 2007 Jun;45(6):44-8. Review.

PMID:
17583229
[PubMed - indexed for MEDLINE]
12.

[Overactive bladder. New anticholinergic drug controls urinary urge].

[No authors listed]

MMW Fortschr Med. 2004 Jul 8;146(27-28):51. German. No abstract available.

PMID:
15526670
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.

Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, Venturini PL, Ferrero S.

Expert Opin Drug Metab Toxicol. 2012 Nov;8(11):1387-408. doi: 10.1517/17425255.2012.714365. Epub 2012 Aug 8. Review.

PMID:
22871042
[PubMed - indexed for MEDLINE]
14.

Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.

Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J; STAR study group.

Eur Urol. 2007 Oct;52(4):1195-203. Epub 2007 Jun 6.

PMID:
17574730
[PubMed - indexed for MEDLINE]
15.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
[PubMed - indexed for MEDLINE]
17.

Trospium chloride for the treatment of overactive bladder with urge incontinence.

Singh-Franco D, Machado C, Tuteja S, Zapantis A.

Clin Ther. 2005 May;27(5):511-30. Review.

PMID:
15978301
[PubMed - indexed for MEDLINE]
18.

Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.

Ho CH, Chang TC, Lin HH, Liu SP, Huang KH, Yu HJ.

J Formos Med Assoc. 2010 Oct;109(10):702-8. doi: 10.1016/S0929-6646(10)60114-3.

PMID:
20970066
[PubMed - indexed for MEDLINE]
19.

Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.

DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.

Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20.

PMID:
22907761
[PubMed - indexed for MEDLINE]
20.

Tolterodine: a clinical review.

Crandall C.

J Womens Health Gend Based Med. 2001 Oct;10(8):735-43. Review.

PMID:
11703885
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk